amivantamab - Robuta Search

https://pubmed.ncbi.nlm.nih.gov/36979929/ Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion... The FDA approval of amivantamab-vmjw, the first bispecific antibody to target the exon20ins mutation, represents an important advancement in the treatment of... https://www.jnj.com/innovativemedicine/emea/janssen-announces-new-data-supporting-safety-profile-and-efficacy-amivantamab-and-lazertinib-0 Janssen Announces New Data Supporting Safety Profile and Efficacy of Amivantamab and Lazertinib... new data safety profile https://adisinsight.springer.com/drugsafety/803784231?error=cookies_not_supported&code=659a3a2e-8d5f-4538-922f-5202a2a51bdf Amivantamab - AdisInsight A 65-year-old man developed pityriasis amiantacea (PA) during treatment with amivantamab for non-small cell lung cancer (NSCLC).The man, who had NSCLC, received amivantamab adisinsight https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-amivantamab-brain-tumour-glioblastoma-5g-emerald Cancer Research UK | A trial looking at amivantamab for a brain tumour called glioblastoma... This trial is looking at amivantamab for high grade glioblastoma. cancer research uk https://pubmed.ncbi.nlm.nih.gov/38012986/ Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC Our real-world multicenter analysis revealed that amivantamab is a potentially effective treatment option for patients with EGFR mutations outside of exon 20... efficacy and safety real world https://www.cancer.gov/research/participate/clinical-trials/intervention/amivantamab Clinical Trials Using Amivantamab - NCI NCI supports clinical trials that test new and more effective ways to treat cancer. Find clinical trials studying amivantamab. clinical trials using amivantamab nci https://ce.massmed.nejm.org/nejm-weekly-cme/content/amivantamab-plus-chemotherapy-nsclc-egfr-exon-20-insertions Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions | MMS/NEJM Continuing Education... https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer | FDA On August 19, 2024, the FDA approved lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for... fda approves lazertinib amivantamab https://pubmed.ncbi.nlm.nih.gov/36868177/ Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS... IRRs with amivantamab were predominantly low grade and limited to first infusion, and rarely occurred with subsequent dosing. Close monitoring for IRR with the... https://data.mendeley.com/datasets/f859xhrp8k/1 Cutaneous toxicities associated with amivantamab in patients with non-small cell lung cancer: A... Supplementary material (table S1, Table S2 and Figure S1). small cell lung cancer https://www.cancer.gov/publications/dictionaries/cancer-terms/def/amivantamab Definition of amivantamab - NCI Dictionary of Cancer Terms - NCI NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine. definition of amivantamab nci dictionary cancer https://adisinsight.springer.com/trials/700375545?error=cookies_not_supported&code=1919aa86-b4ce-4031-b682-8edcaf2f5232 A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination... The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants